Literature DB >> 10085033

Mapping of staphylococcal enterotoxin A functional binding sites and presentation by monoclonal antibodies and fusion proteins.

W Mahana1.   

Abstract

Staphylococal enterotoxins (SE) bind with high affinity to major histocompatibility complex (MHC) class II proteins and stimulate large number of T cells via the Vbeta region of the T-cell receptor (TCR). To map the epitopes of SE type A (SEA) involved in MHC binding and cell proliferation, 20 specific anti-SEA monoclonal antibodies (MAbs) and two large glutathione S-transferase fusion proteins corresponding to the amino and carboxy termini, respectively, of SEA were used. The functionality of these antibodies was tested, by MHC binding inhibition, interleukin-2 production, and T-cell proliferation assays. Moreover, I studied the ability of the MAbs to present SEA in vitro to human and murine cells and their reactivity with the two fusion proteins. This study showed that all of the MAbs have a defined effect on one or both immunological properties of SEA and were able to present SEA to human and murine cells. However, one MAb (4H8) recognized SEA but without any interference with its biological activities. When the MAbs were tested to react with the two fusion proteins representing the SEA molecule, all of the MAbs were negative except for two. These results confirmed the presence of two functionally different binding sites of SEA with MHC class II molecules and the importance of the disulfide loop for the mitogenic activity of SEA. I further demonstrated that MAbs can present SEA to immune cells independent of the site recognized by the antibody and that the integrity of the SEA molecule is very important for its functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085033      PMCID: PMC96543          DOI: 10.1128/IAI.67.4.1894-1900.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins.

Authors:  M Dohlsten; P A Lando; G Hedlund; J Trowsdale; T Kalland
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

3.  Structural basis for differential binding of staphylococcal enterotoxin A and toxic shock syndrome toxin 1 to class II major histocompatibility molecules.

Authors:  C H Pontzer; J K Russell; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

Review 4.  T cell receptor gene diversity and selection.

Authors:  M M Davis
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

5.  Mutant human B cell lines deficient in class II major histocompatibility complex transcription.

Authors:  A F Calman; B M Peterlin
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

6.  High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR.

Authors:  J D Fraser
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

7.  Localization of an immune functional site on staphylococcal enterotoxin A using the synthetic peptide approach.

Authors:  C H Pontzer; J K Russell; H M Johnson
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

8.  Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.

Authors:  J Thibodeau; I Cloutier; P M Lavoie; N Labrecque; W Mourad; T Jardetzky; R P Sékaly
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

9.  Site of nonrestrictive binding of SEA to class II MHC antigens.

Authors:  C H Pontzer; J K Russell; M A Jarpe; H M Johnson
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

10.  Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules.

Authors:  P Scholl; A Diez; W Mourad; J Parsonnet; R S Geha; T Chatila
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.